IFNG and exocrine pancreatic carcinoma: In fact, IFN-γ treatment had no contribution to the outcomes of patients with metastatic renal cell carcinomas (265), leukemia (266), pancreatic carcinoma (267), breast cancer (268), or into the postoperative surgical therapy for colon cancer (269).